RO has received speaker honoraria from Meiji Seika Pharma Co., Ltd. MS has received consulting fees from Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd.; speaker honoraria from EA Pharma Co., Ltd., Eisai Co., Ltd., Daiichi-Sankyo Co., Ltd., Kao Corporation, Kowa Co., Ltd., Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Viatris Inc., and Yoshitomi Pharmaceutical Industries, Ltd.; payment for expert testimony from Eisai Co., Ltd., Jazz Pharmaceuticals Inc., Kao Corporation, Mochida Pharmaceutical Co., Ltd., Nxera Pharma Co., Ltd., and Shionogi & Co., Ltd.; and personal compensation for serving on a Scientific Advisory or Data Safety Monitoring board from Novartis Pharma K.K. NF has received speaker honoraria from Sumitomo Pharma Co., Ltd. JK has received speaker honoraria from Meiji Seika Pharma Co., Ltd. YK has received speaker honoraria from Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., and Viatris Inc. The other authors declare that they have no conflicts of interest.

This study was approved by the Ethics Committee of Nihon University Itabashi Hospital (RK-2209139).